1995 - 1996 HIGH SENSITIVE DETECTION FOR gp41 AND p24 of HUMAN IMMUNODEFICIENCY VIRUS BY THE USE OF CHEMICAL SENSOR
1993 - 1994 DETECTION OF PROTEINS OF HUMAN IMMUNODEFICIENCY VIRUS BY USING CHEMICAL SENSOR
バイオセンサーの研究開発
ガン関連診断薬の研究と応用
抗体の分子デザインと人工酵素
Study on Biosensors using antibodies specific to many antigens
Development and practical appreciation of cancer diagnosis
Molecular design of immunoglobulin and artificial enzyme
Show all
Papers (56):
Emi Hifumi, Yuina Ito, Moe Tsujita, Hiroaki Taguchi, Taizo Uda. Enzymatization of mouse monoclonal antibodies to the corresponding catalytic antibodies. Scientific reports. 2024. 14. 1. 12184-12184
Emi HIFUMI, Hiroaki TAGUCHI, Tamami NONAKA, Taizo UDA. Direct conversion of a general antibody to its catalytic antibody and corresponding applications -Importance and role of Pro95 in CDR-3-. Proceedings of the Japan Academy, Series B. 2023. 99. 6. 155-172
Tamami Nonaka, Hiroaki Taguchi, Taizo Uda, Emi Hifumi. Obtaining Highly Active Catalytic Antibodies Capable of Enzymatically Cleaving Antigens. International Journal of Molecular Sciences. 2022. 23. 22. 14351-14351
Emi Hifumi, Tamami Nonaka, Hiroaki Taguchi, Taizo Uda. A new catalytic site functioning in antigen cleavage by H34 catalytic antibody light chain. Scientific Reports. 2022. 12. 1
Emi Hifumi, Hiroaki Taguchi, Tamami Nonaka, Takunori Harada, Taizo Uda. Finding and characterizing a catalytic antibody light chain, H34, capable of degrading the PD-1 molecule. RSC Chemical Biology. 2021. 2. 1. 220-229
Emi Hifumi, Hiroaki Taguchi, Haruna Tsuda, Tetsuro Minagawa, Tamami Nonaka, Taizo Uda. A new algorithm to convert a normal antibody into the corresponding catalytic antibody. Science advances. 2020. 6. 13. eaay6441
E. Hifumi, H. Taguchi, R. Kato, M. Arakawa, Y. Katayama, T. Uda. Structural diversity problem of antibodies and catalytic antibody light chains and the solving method. Antibody Engineering. 2018. Chapter 10. 231-257
E. Hifumi, M. Arakawa, T. Uda. Preparation and perspectives of catalytic antibodies possessing characteristic ability to inhibit infection against viruses such as influenza and rabies. Frontiers in Clinical Drug Research-Anti Infectives. 2017. Vol. 4. 28-57